Nilceya

Overview

nilotinib

kinase inhibitor

• CYP3A4 substrate
• CYP3A4 inhibitor, moderate
• antiplatelet/anticoagulant effects
• gastric pH sensitive
• GI mucosal injury/bleeding risk
• hyperkalemia
• hyperuricemic effects
• hypocalcemia
• hypokalemia
• hyponatremia
• hypophosphatemia
• immunomodulatory effects
• myelosuppressive oncologic agent
• prolongs QT interval (known)

Contraindicated

• cisapride
Nilceya (nilotinib)

+

cisapride

1 interaction

Contraindicated

nilotinib + cisapride

contraindicated: combo may incr. cisapride levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• colchicine
Nilceya (nilotinib)

+

colchicine

1 interaction

Contraindicated

nilotinib + colchicine

CV RISK: avoid combo if renal or hepatic impairment; otherwise, monitor CBC, CK, myopathy s/sx; GOUT or FMF: contraindicated if renal or hepatic impairment; otherwise, use alternative or monitor CBC; decr. colchicine dose during and x14 days after nilotinib use: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT: avoid combo if receiving colchicine for prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myelosuppression, myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metab. inhibited, additive effects)

• domperidone
Nilceya (nilotinib)

+

domperidone

1 interaction

Contraindicated

nilotinib + domperidone

contraindicated: combo may incr. domperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lomitapide
Nilceya (nilotinib)

+

lomitapide

2 interactions

Contraindicated

nilotinib + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of adverse effects (hepatic metab. inhibited)

• posaconazole
Nilceya (nilotinib)

+

posaconazole

2 interactions

Contraindicated

nilotinib + posaconazole

contraindicated: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metab. inhibited; additive effects)

• thioridazine
Nilceya (nilotinib)

+

thioridazine

2 interactions

Contraindicated

nilotinib + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Nilceya (nilotinib)

+

ziprasidone

1 interaction

Contraindicated

nilotinib + ziprasidone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

• alfentanil
Nilceya (nilotinib)

+

alfentanil

1 interaction

Avoid/Use Alternative

nilotinib + alfentanil

use alternative or monitor resp. rate; consider decr. alfentanil dose: combo may incr. alfentanil levels, risk of CNS and resp. depression, psychomotor impairment, delayed recovery from anesthesia, other adverse effects (hepatic metab. inhibited)

• alprazolam
Nilceya (nilotinib)

+

alprazolam

1 interaction

Avoid/Use Alternative

nilotinib + alprazolam

use alternative or monitor resp. rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• amiloride
Nilceya (nilotinib)

+

amiloride

1 interaction

Avoid/Use Alternative

nilotinib + amiloride

if hypokalemia use, monitor potassium, sodium; otherwise, avoid combo: combo may incr. risk of hyperkalemia, hyponatremia (additive effects)

• amiodarone
Nilceya (nilotinib)

+

amiodarone

1 interaction

Avoid/Use Alternative

nilotinib + amiodarone

avoid combo: combo may incr. amiodarone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• anagrelide
Nilceya (nilotinib)

+

anagrelide

1 interaction

Avoid/Use Alternative

nilotinib + anagrelide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• apalutamide
Nilceya (nilotinib)

+

apalutamide

1 interaction

Avoid/Use Alternative

nilotinib + apalutamide

avoid combo: combo may decr. nilotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• arsenic trioxide
Nilceya (nilotinib)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

nilotinib + arsenic trioxide

avoid combo: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Nilceya (nilotinib)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

nilotinib + artemether/ lumefantrine

avoid combo: combo may incr. artemether/lumefantrine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• cenobamate
Nilceya (nilotinib)

+

cenobamate

1 interaction

Avoid/Use Alternative

nilotinib + cenobamate

consider alternative: combo may decr. nilotinib levels, efficacy (hepatic metab. induced)

• ceritinib
Nilceya (nilotinib)

+

ceritinib

1 interaction

Avoid/Use Alternative

nilotinib + ceritinib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• chikungunya vaccine, live
Nilceya (nilotinib)

+

chikungunya vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + chikungunya vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• chloramphenicol
Nilceya (nilotinib)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

nilotinib + chloramphenicol

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• desflurane
Nilceya (nilotinib)

+

desflurane

1 interaction

Avoid/Use Alternative

nilotinib + desflurane

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• desipramine
Nilceya (nilotinib)

+

desipramine

1 interaction

Avoid/Use Alternative

nilotinib + desipramine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• dexlansoprazole
Nilceya (nilotinib)

+

dexlansoprazole

1 interaction

Avoid/Use Alternative

nilotinib + dexlansoprazole

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• dexmedetomidine
Nilceya (nilotinib)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

nilotinib + dexmedetomidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexmedetomidine injection
Nilceya (nilotinib)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

nilotinib + dexmedetomidine injection

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexrazoxane
Nilceya (nilotinib)

+

dexrazoxane

1 interaction

Avoid/Use Alternative

nilotinib + dexrazoxane

monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

• dihydrocodeine
Nilceya (nilotinib)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

nilotinib + dihydrocodeine

use alternative or monitor resp. rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited, may incr. production of active metabolite dihydromorphine)

• dihydroergotamine
Nilceya (nilotinib)

+

dihydroergotamine

1 interaction

Avoid/Use Alternative

nilotinib + dihydroergotamine

use alternative: combo may incr. dihydroergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• disopyramide
Nilceya (nilotinib)

+

disopyramide

1 interaction

Avoid/Use Alternative

nilotinib + disopyramide

avoid combo: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• dofetilide
Nilceya (nilotinib)

+

dofetilide

1 interaction

Avoid/Use Alternative

nilotinib + dofetilide

avoid combo: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• donepezil
Nilceya (nilotinib)

+

donepezil

1 interaction

Avoid/Use Alternative

nilotinib + donepezil

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• dordaviprone
Nilceya (nilotinib)

+

dordaviprone

1 interaction

Avoid/Use Alternative

nilotinib + dordaviprone

avoid combo: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• doxorubicin
Nilceya (nilotinib)

+

doxorubicin

1 interaction

Avoid/Use Alternative

nilotinib + doxorubicin

avoid combo: combo may incr. doxorubicin levels, risk serious infection, myelosuppression, cardiotoxicity, other adverse effects (hepatic metab. inhibited)

• droperidol
Nilceya (nilotinib)

+

droperidol

1 interaction

Avoid/Use Alternative

nilotinib + droperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• efavirenz
Nilceya (nilotinib)

+

efavirenz

1 interaction

Avoid/Use Alternative

nilotinib + efavirenz

consider alternative: combo may decr. nilotinib levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias (hepatic metab. induced; additive effects)

• elacestrant
Nilceya (nilotinib)

+

elacestrant

1 interaction

Avoid/Use Alternative

nilotinib + elacestrant

avoid combo: combo may incr. elacestrant levels, risk of adverse effects (hepatic metab. inhibited)

• encorafenib
Nilceya (nilotinib)

+

encorafenib

2 interactions

Avoid/Use Alternative

nilotinib + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, GI or other bleeding (incl. life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• ensartinib
Nilceya (nilotinib)

+

ensartinib

2 interactions

Avoid/Use Alternative

nilotinib + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metab. possibly inhibited)

• entrectinib
Nilceya (nilotinib)

+

entrectinib

2 interactions

Avoid/Use Alternative

nilotinib + entrectinib

avoid combo: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• enzalutamide
Nilceya (nilotinib)

+

enzalutamide

2 interactions

Avoid/Use Alternative

nilotinib + enzalutamide

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metab. induced)

• ephedra
Nilceya (nilotinib)

+

ephedra

2 interactions

Avoid/Use Alternative

nilotinib + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Nilceya (nilotinib)

+

epirubicin

2 interactions

Avoid/Use Alternative

nilotinib + epirubicin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erdafitinib
Nilceya (nilotinib)

+

erdafitinib

2 interactions

Avoid/Use Alternative

nilotinib + erdafitinib

avoid combo until after dose titration period at 14-21 days post erdafitinib tx initiation; otherwise, monitor phosphate: combo may interfere w/ erdafitinib dose titration; may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (altered phosphate levels; hepatic metab. inhibited)

• ergotamine
Nilceya (nilotinib)

+

ergotamine

2 interactions

Avoid/Use Alternative

nilotinib + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metab. inhibited)

• eribulin
Nilceya (nilotinib)

+

eribulin

2 interactions

Avoid/Use Alternative

nilotinib + eribulin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Nilceya (nilotinib)

+

erythromycin

2 interactions

Avoid/Use Alternative

nilotinib + erythromycin

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• fexinidazole
Nilceya (nilotinib)

+

fexinidazole

1 interaction

Avoid/Use Alternative

nilotinib + fexinidazole

avoid combo: combo may decr. nilotinib levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy; may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (hepatic metab. induced; hepatic metab. inhibited, decr. conversion to active metabolites; additive effects)

• fingolimod
Nilceya (nilotinib)

+

fingolimod

1 interaction

Avoid/Use Alternative

nilotinib + fingolimod

monitor electrolytes, ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Nilceya (nilotinib)

+

flecainide

1 interaction

Avoid/Use Alternative

nilotinib + flecainide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluconazole
Nilceya (nilotinib)

+

fluconazole

1 interaction

Avoid/Use Alternative

nilotinib + fluconazole

use alternative or monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• fluorouracil
Nilceya (nilotinib)

+

fluorouracil

1 interaction

Avoid/Use Alternative

nilotinib + fluorouracil

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Nilceya (nilotinib)

+

fluoxetine

1 interaction

Avoid/Use Alternative

nilotinib + fluoxetine

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fosaprepitant
Nilceya (nilotinib)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

nilotinib + fosaprepitant

avoid combo: combo may incr. aprepitant levels, risk of adverse effects (hepatic metab. inhibited)

• foscarnet
Nilceya (nilotinib)

+

foscarnet

1 interaction

Avoid/Use Alternative

nilotinib + foscarnet

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of severe hypocalcemia, hypokalemia, QT prolongation, cardiac arrhythmias, tetany, seizures, myelosuppression (additive effects)

• fosphenytoin
Nilceya (nilotinib)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

nilotinib + fosphenytoin

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metab. induced)

• ganciclovir
Nilceya (nilotinib)

+

ganciclovir

1 interaction

Avoid/Use Alternative

nilotinib + ganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• gemtuzumab ozogamicin
Nilceya (nilotinib)

+

gemtuzumab ozogamicin

1 interaction

Avoid/Use Alternative

nilotinib + gemtuzumab ozogamicin

monitor ECG, electrolytes, platelets, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• gepotidacin
Nilceya (nilotinib)

+

gepotidacin

1 interaction

Avoid/Use Alternative

nilotinib + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Nilceya (nilotinib)

+

gilteritinib

1 interaction

Avoid/Use Alternative

nilotinib + gilteritinib

avoid combo: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• givinostat
Nilceya (nilotinib)

+

givinostat

1 interaction

Avoid/Use Alternative

nilotinib + givinostat

use alternative or monitor CBC, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• glasdegib
Nilceya (nilotinib)

+

glasdegib

1 interaction

Avoid/Use Alternative

nilotinib + glasdegib

avoid combo: combo may incr. glasdegib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• goserelin
Nilceya (nilotinib)

+

goserelin

2 interactions

Avoid/Use Alternative

nilotinib + goserelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Nilceya (nilotinib)

+

grapefruit

2 interactions

Avoid/Use Alternative

nilotinib + grapefruit

avoid grapefruit juice: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (GI metab. inhibited, additive effects)

• haloperidol
Nilceya (nilotinib)

+

haloperidol

2 interactions

Avoid/Use Alternative

nilotinib + haloperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• histrelin
Nilceya (nilotinib)

+

histrelin

2 interactions

Avoid/Use Alternative

nilotinib + histrelin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• hydrocodone
Nilceya (nilotinib)

+

hydrocodone

2 interactions

Avoid/Use Alternative

nilotinib + hydrocodone

use alternative or monitor resp. rate, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• hydroxychloroquine
Nilceya (nilotinib)

+

hydroxychloroquine

2 interactions

Avoid/Use Alternative

nilotinib + hydroxychloroquine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• hydroxyzine
Nilceya (nilotinib)

+

hydroxyzine

2 interactions

Avoid/Use Alternative

nilotinib + hydroxyzine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ibutilide
Nilceya (nilotinib)

+

ibutilide

2 interactions

Avoid/Use Alternative

nilotinib + ibutilide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• idelalisib
Nilceya (nilotinib)

+

idelalisib

2 interactions

Avoid/Use Alternative

nilotinib + idelalisib

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• iloperidone
Nilceya (nilotinib)

+

iloperidone

2 interactions

Avoid/Use Alternative

nilotinib + iloperidone

use alternative or monitor ECG, electrolytes: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• influenza nasal vaccine, live
Nilceya (nilotinib)

+

influenza nasal vaccine, live

2 interactions

Avoid/Use Alternative

nilotinib + influenza nasal vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• inotuzumab ozogamicin
Nilceya (nilotinib)

+

inotuzumab ozogamicin

2 interactions

Avoid/Use Alternative

nilotinib + inotuzumab ozogamicin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midazolam
Nilceya (nilotinib)

+

midazolam

1 interaction

Avoid/Use Alternative

nilotinib + midazolam

avoid combo if midazolam nasal use; otherwise, monitor resp. rate, consider decr. midazolam dose: combo may incr. midazolam and active metabolite levels, risk of profound CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• pazopanib
Nilceya (nilotinib)

+

pazopanib

1 interaction

Avoid/Use Alternative

nilotinib + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• pemigatinib
Nilceya (nilotinib)

+

pemigatinib

2 interactions

Avoid/Use Alternative

nilotinib + pemigatinib

use alternative or monitor phosphate and decr. pemigatinib dose as follows: if on pemigatinib 13.5 mg qd, decr. to 9 mg qd; if on pemigatinib 9 mg qd, decr. to 4.5 mg qd: combo may incr. pemigatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• penicillamine
Nilceya (nilotinib)

+

penicillamine

2 interactions

Avoid/Use Alternative

nilotinib + penicillamine

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pentamidine
Nilceya (nilotinib)

+

pentamidine

1 interaction

Avoid/Use Alternative

nilotinib + pentamidine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypocalcemia (additive effects)

• pexidartinib
Nilceya (nilotinib)

+

pexidartinib

1 interaction

Avoid/Use Alternative

nilotinib + pexidartinib

consider alternative: combo may incr. pexidartinib levels, risk of hepatotoxicity, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• phenytoin
Nilceya (nilotinib)

+

phenytoin

1 interaction

Avoid/Use Alternative

nilotinib + phenytoin

avoid combo: combo may decr. nilotinib levels, efficacy (hepatic metab. induced)

• pitolisant
Nilceya (nilotinib)

+

pitolisant

1 interaction

Avoid/Use Alternative

nilotinib + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• potassium phosphate
Nilceya (nilotinib)

+

potassium phosphate

1 interaction

Avoid/Use Alternative

nilotinib + potassium phosphate

use alternative or monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• primaquine
Nilceya (nilotinib)

+

primaquine

1 interaction

Avoid/Use Alternative

nilotinib + primaquine

use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

• procainamide
Nilceya (nilotinib)

+

procainamide

1 interaction

Avoid/Use Alternative

nilotinib + procainamide

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• propafenone
Nilceya (nilotinib)

+

propafenone

1 interaction

Avoid/Use Alternative

nilotinib + propafenone

avoid combo: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metab. inhibited, additive effects)

• radium Ra 223 dichloride
Nilceya (nilotinib)

+

radium Ra 223 dichloride

1 interaction

Avoid/Use Alternative

nilotinib + radium Ra 223 dichloride

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• revumenib
Nilceya (nilotinib)

+

revumenib

1 interaction

Avoid/Use Alternative

nilotinib + revumenib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Nilceya (nilotinib)

+

ribociclib

1 interaction

Avoid/Use Alternative

nilotinib + ribociclib

avoid combo: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• ritonavir
Nilceya (nilotinib)

+

ritonavir

1 interaction

Avoid/Use Alternative

nilotinib + ritonavir

use alternative or monitor ECG, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• romidepsin
Nilceya (nilotinib)

+

romidepsin

1 interaction

Avoid/Use Alternative

nilotinib + romidepsin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypocalcemia, hyponatremia (additive effects)

• ropeginterferon alfa-2b
Nilceya (nilotinib)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

nilotinib + ropeginterferon alfa-2b

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rotavirus vaccine, live
Nilceya (nilotinib)

+

rotavirus vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + rotavirus vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• rucaparib
Nilceya (nilotinib)

+

rucaparib

1 interaction

Avoid/Use Alternative

nilotinib + rucaparib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selumetinib
Nilceya (nilotinib)

+

selumetinib

2 interactions

Avoid/Use Alternative

nilotinib + selumetinib

use alternative or monitor LVEF, CK, myopathy sx, bleeding s/sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• sertraline
Nilceya (nilotinib)

+

sertraline

1 interaction

Avoid/Use Alternative

nilotinib + sertraline

use alternative or monitor ECG, electrolytes, bleeding s/sx: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited; additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• typhoid vaccine, live
Nilceya (nilotinib)

+

typhoid vaccine, live

2 interactions

Avoid/Use Alternative

nilotinib + typhoid vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• valganciclovir
Nilceya (nilotinib)

+

valganciclovir

1 interaction

Avoid/Use Alternative

nilotinib + valganciclovir

use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• valsartan
Nilceya (nilotinib)

+

valsartan

1 interaction

Avoid/Use Alternative

nilotinib + valsartan

consider alternative or monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• vandetanib
Nilceya (nilotinib)

+

vandetanib

1 interaction

Avoid/Use Alternative

nilotinib + vandetanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, GI or other bleeding, incl. life-threatening (additive effects)

• vardenafil
Nilceya (nilotinib)

+

vardenafil

1 interaction

Avoid/Use Alternative

nilotinib + vardenafil

monitor ECG, electrolytes; max vardenafil dose 5 mg/24h; avoid combo w/ ODT form: combo may incr. vardenafil levels, risk of QT prolongation, cardiac arrhythmias, hypotension, priapism, other adverse effects (hepatic metab. inhibited, additive effects)

• varicella vaccine, live
Nilceya (nilotinib)

+

varicella vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + varicella vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

• vemurafenib
Nilceya (nilotinib)

+

vemurafenib

1 interaction

Avoid/Use Alternative

nilotinib + vemurafenib

avoid combo: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• venetoclax
Nilceya (nilotinib)

+

venetoclax

1 interaction

Avoid/Use Alternative

nilotinib + venetoclax

monitor CBC, tumor lysis syndrome s/sx; CLL/SLL: consider alternative or decr. venetoclax dose by at least 50%; AML: decr. venetoclax dose by at least 50%: combo may incr. venetoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metab. inhibited)

• vonoprazan
Nilceya (nilotinib)

+

vonoprazan

1 interaction

Avoid/Use Alternative

nilotinib + vonoprazan

use alternative, incl. H2 blockers 10h before or 2h after nilotinib or short-acting antacids 2h before or 2h after nilotinib: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• voriconazole
Nilceya (nilotinib)

+

voriconazole

1 interaction

Avoid/Use Alternative

nilotinib + voriconazole

use alternative or monitor ECG, electrolytes, CBC; decr. nilotinib dose as follows: newly diagnosed CML: if on nilotinib 300 mg bid, decr. to 200 mg qd; if on nilotinib 142 mg bid, decr. to 95 mg qd; resistant or intolerant CML: if on nilotinib 400 mg bid, decr. to 300 mg qd; if on nilotinib 190 mg bid, decr. to 142 mg qd: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• yellow fever vaccine, live
Nilceya (nilotinib)

+

yellow fever vaccine, live

1 interaction

Avoid/Use Alternative

nilotinib + yellow fever vaccine, live

avoid combo; vaccinate at least 4wk before or 3-6mo after nilotinib tx: combo may result in inadequate vaccine response, incr. risk of disseminated infection (immunosuppressive effects)

Monitor/Modify Tx

• abemaciclib
Nilceya (nilotinib)

+

abemaciclib

1 interaction

Monitor/Modify Tx

nilotinib + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of serious infection, myelosuppression, thrombosis risk, other adverse effects (hepatic metab. inhibited)

• abiraterone acetate
Nilceya (nilotinib)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

nilotinib + abiraterone acetate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• acalabrutinib
Nilceya (nilotinib)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

nilotinib + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC, bleeding s/sx: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• acetazolamide
Nilceya (nilotinib)

+

acetazolamide

1 interaction

Monitor/Modify Tx

nilotinib + acetazolamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• ado-trastuzumab emtansine
Nilceya (nilotinib)

+

ado-trastuzumab emtansine

1 interaction

Monitor/Modify Tx

nilotinib + ado-trastuzumab emtansine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• afatinib
Nilceya (nilotinib)

+

afatinib

1 interaction

Monitor/Modify Tx

nilotinib + afatinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• albendazole
Nilceya (nilotinib)

+

albendazole

1 interaction

Monitor/Modify Tx

nilotinib + albendazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• albuterol
Nilceya (nilotinib)

+

albuterol

1 interaction

Monitor/Modify Tx

nilotinib + albuterol

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• albuterol inhaled
Nilceya (nilotinib)

+

albuterol inhaled

2 interactions

Monitor/Modify Tx

nilotinib + albuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• alemtuzumab
Nilceya (nilotinib)

+

alemtuzumab

2 interactions

Monitor/Modify Tx

nilotinib + alemtuzumab

monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

• alendronate
Nilceya (nilotinib)

+

alendronate

1 interaction

Monitor/Modify Tx

nilotinib + alendronate

monitor calcium, bleeding s/sx: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• alfuzosin
Nilceya (nilotinib)

+

alfuzosin

1 interaction

Monitor/Modify Tx

nilotinib + alfuzosin

monitor BP, ECG, electrolytes: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited, additive effects)

• aliskiren
Nilceya (nilotinib)

+

aliskiren

1 interaction

Monitor/Modify Tx

nilotinib + aliskiren

monitor potassium: combo may incr. aliskiren levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited, additive effects)

• allopurinol
Nilceya (nilotinib)

+

allopurinol

1 interaction

Monitor/Modify Tx

nilotinib + allopurinol

monitor CBC, uric acid levels: combo may incr. risk of myelosuppression; may decr. allopurinol efficacy (additive effects; antagonistic effects)

• aloe
Nilceya (nilotinib)

+

aloe

1 interaction

Monitor/Modify Tx

nilotinib + aloe

monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

• alteplase
Nilceya (nilotinib)

+

alteplase

1 interaction

Monitor/Modify Tx

nilotinib + alteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• aluminum hydroxide
Nilceya (nilotinib)

+

aluminum hydroxide

1 interaction

Monitor/Modify Tx

nilotinib + aluminum hydroxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• amifostine
Nilceya (nilotinib)

+

amifostine

1 interaction

Monitor/Modify Tx

nilotinib + amifostine

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• amisulpride
Nilceya (nilotinib)

+

amisulpride

1 interaction

Monitor/Modify Tx

nilotinib + amisulpride

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amitriptyline
Nilceya (nilotinib)

+

amitriptyline

1 interaction

Monitor/Modify Tx

nilotinib + amitriptyline

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amphotericin
Nilceya (nilotinib)

+

amphotericin

1 interaction

Monitor/Modify Tx

nilotinib + amphotericin

monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

• anacaulase topical
Nilceya (nilotinib)

+

anacaulase topical

1 interaction

Monitor/Modify Tx

nilotinib + anacaulase topical

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• anthrax vaccine
Nilceya (nilotinib)

+

anthrax vaccine

1 interaction

Monitor/Modify Tx

nilotinib + anthrax vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• anti-thymocyte globulin
Nilceya (nilotinib)

+

anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

nilotinib + anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• antithrombin
Nilceya (nilotinib)

+

antithrombin

1 interaction

Monitor/Modify Tx

nilotinib + antithrombin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• apixaban
Nilceya (nilotinib)

+

apixaban

1 interaction

Monitor/Modify Tx

nilotinib + apixaban

monitor bleeding s/sx, especially if also combined w/ P-gp inhibitor: combo may incr. apixaban levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• arformoterol inhaled
Nilceya (nilotinib)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + arformoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• argatroban
Nilceya (nilotinib)

+

argatroban

1 interaction

Monitor/Modify Tx

nilotinib + argatroban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• aripiprazole oral
Nilceya (nilotinib)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

nilotinib + aripiprazole oral

consider decr. PO aripiprazole dose; if also CYP2D6 PM or if also combined w/ strong CYP2D6 inhibitor, consider decr. PO aripiprazole dose up to 75%; no dose adjustment if depression adjunct tx use: combo may incr. aripiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• asciminib
Nilceya (nilotinib)

+

asciminib

1 interaction

Monitor/Modify Tx

nilotinib + asciminib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asparaginase
Nilceya (nilotinib)

+

asparaginase

1 interaction

Monitor/Modify Tx

nilotinib + asparaginase

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI or other bleeding, incl. life-threatening (additive effects)

• aspirin
Nilceya (nilotinib)

+

aspirin

1 interaction

Monitor/Modify Tx

nilotinib + aspirin

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• atidarsagene autotemcel
Nilceya (nilotinib)

+

atidarsagene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + atidarsagene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• atorvastatin
Nilceya (nilotinib)

+

atorvastatin

1 interaction

Monitor/Modify Tx

nilotinib + atorvastatin

monitor CK, myopathy sx: combo may incr. atorvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited)

• auranofin
Nilceya (nilotinib)

+

auranofin

1 interaction

Monitor/Modify Tx

nilotinib + auranofin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• avacopan
Nilceya (nilotinib)

+

avacopan

1 interaction

Monitor/Modify Tx

nilotinib + avacopan

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• avanafil
Nilceya (nilotinib)

+

avanafil

1 interaction

Monitor/Modify Tx

nilotinib + avanafil

monitor BP; adjust max avanafil dose to 50 mg/24h: combo may incr. avanafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• avatrombopag
Nilceya (nilotinib)

+

avatrombopag

1 interaction

Monitor/Modify Tx

nilotinib + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets, thrombosis s/sx; if avatrombopag tablet also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 20 mg 3x/wk; if avatrombopag sprinkle also combined w/ a moderate or strong CYP2C9 inhibitor, decr. start dose to 10 mg 3x/wk; CHRONIC LIVER DZ: monitor platelets, thrombosis s/sx: combo may incr. avatrombopag levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• axitinib
Nilceya (nilotinib)

+

axitinib

1 interaction

Monitor/Modify Tx

nilotinib + axitinib

monitor bleeding s/sx; consider decr. axitinib dose: combo may incr. axitinib levels, risk of GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• azathioprine
Nilceya (nilotinib)

+

azathioprine

1 interaction

Monitor/Modify Tx

nilotinib + azathioprine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• benazepril
Nilceya (nilotinib)

+

benazepril

2 interactions

Monitor/Modify Tx

nilotinib + benazepril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• benznidazole
Nilceya (nilotinib)

+

benznidazole

2 interactions

Monitor/Modify Tx

nilotinib + benznidazole

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• berotralstat
Nilceya (nilotinib)

+

berotralstat

1 interaction

Monitor/Modify Tx

nilotinib + berotralstat

monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• betamethasone
Nilceya (nilotinib)

+

betamethasone

1 interaction

Monitor/Modify Tx

nilotinib + betamethasone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• betibeglogene autotemcel
Nilceya (nilotinib)

+

betibeglogene autotemcel

2 interactions

Monitor/Modify Tx

nilotinib + betibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• bevacizumab
Nilceya (nilotinib)

+

bevacizumab

1 interaction

Monitor/Modify Tx

nilotinib + bevacizumab

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• binimetinib
Nilceya (nilotinib)

+

binimetinib

1 interaction

Monitor/Modify Tx

nilotinib + binimetinib

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bivalirudin
Nilceya (nilotinib)

+

bivalirudin

1 interaction

Monitor/Modify Tx

nilotinib + bivalirudin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• brentuximab vedotin
Nilceya (nilotinib)

+

brentuximab vedotin

1 interaction

Monitor/Modify Tx

nilotinib + brentuximab vedotin

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• brexpiprazole
Nilceya (nilotinib)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

nilotinib + brexpiprazole

if CYP2D6 poor metabolizer or if also combined w/ moderate or strong CYP2D6 inhibitor, decr. brexpiprazole dose 75%: combo may incr. brexpiprazole levels, risk of adverse effects (hepatic metab. inhibited)

• bromelain
Nilceya (nilotinib)

+

bromelain

1 interaction

Monitor/Modify Tx

nilotinib + bromelain

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• bromfenac ophthalmic
Nilceya (nilotinib)

+

bromfenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + bromfenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• budesonide
Nilceya (nilotinib)

+

budesonide

1 interaction

Monitor/Modify Tx

nilotinib + budesonide

monitor potassium, hypercorticism s/sx: combo may incr. budesonide levels, risk of systemic corticosteroid effects, incl. Cushing syndrome, adrenal suppression, serious infection, hypokalemia, other adverse effects (hepatic metab. inhibited, additive effects)

• bumetanide
Nilceya (nilotinib)

+

bumetanide

1 interaction

Monitor/Modify Tx

nilotinib + bumetanide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• buprenorphine
Nilceya (nilotinib)

+

buprenorphine

1 interaction

Monitor/Modify Tx

nilotinib + buprenorphine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• butorphanol
Nilceya (nilotinib)

+

butorphanol

1 interaction

Monitor/Modify Tx

nilotinib + butorphanol

monitor resp. rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• cabazitaxel
Nilceya (nilotinib)

+

cabazitaxel

1 interaction

Monitor/Modify Tx

nilotinib + cabazitaxel

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• calaspargase
Nilceya (nilotinib)

+

calaspargase

1 interaction

Monitor/Modify Tx

nilotinib + calaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• calcitonin-salmon
Nilceya (nilotinib)

+

calcitonin-salmon

1 interaction

Monitor/Modify Tx

nilotinib + calcitonin-salmon

monitor calcium: combo may incr. risk of hypocalcemia, tetany, seizures (additive effects)

• calcium carbonate
Nilceya (nilotinib)

+

calcium carbonate

1 interaction

Monitor/Modify Tx

nilotinib + calcium carbonate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• candesartan cilexetil
Nilceya (nilotinib)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

nilotinib + candesartan cilexetil

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• cangrelor
Nilceya (nilotinib)

+

cangrelor

1 interaction

Monitor/Modify Tx

nilotinib + cangrelor

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• capivasertib
Nilceya (nilotinib)

+

capivasertib

1 interaction

Monitor/Modify Tx

nilotinib + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metab. inhibited)

• caplacizumab
Nilceya (nilotinib)

+

caplacizumab

1 interaction

Monitor/Modify Tx

nilotinib + caplacizumab

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• captopril
Nilceya (nilotinib)

+

captopril

1 interaction

Monitor/Modify Tx

nilotinib + captopril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• carfilzomib
Nilceya (nilotinib)

+

carfilzomib

1 interaction

Monitor/Modify Tx

nilotinib + carfilzomib

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI or other bleeding, incl. life-threatening (additive effects)

• cariprazine
Nilceya (nilotinib)

+

cariprazine

1 interaction

Monitor/Modify Tx

nilotinib + cariprazine

if starting cariprazine tx, adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 1.5 mg qod, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 1.5 mg qod; if on stable cariprazine tx and starting nilotinib, adjust cariprazine dose as follows: ALL INDICATIONS: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 1.5 mg qod; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metab. inhibited)

• celecoxib
Nilceya (nilotinib)

+

celecoxib

1 interaction

Monitor/Modify Tx

nilotinib + celecoxib

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• cetuximab
Nilceya (nilotinib)

+

cetuximab

1 interaction

Monitor/Modify Tx

nilotinib + cetuximab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• chikungunya vaccine
Nilceya (nilotinib)

+

chikungunya vaccine

1 interaction

Monitor/Modify Tx

nilotinib + chikungunya vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• chlorothiazide
Nilceya (nilotinib)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

nilotinib + chlorothiazide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia, seizures (additive effects)

• chlorthalidone
Nilceya (nilotinib)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

nilotinib + chlorthalidone

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• cidofovir
Nilceya (nilotinib)

+

cidofovir

1 interaction

Monitor/Modify Tx

nilotinib + cidofovir

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• cilostazol
Nilceya (nilotinib)

+

cilostazol

1 interaction

Monitor/Modify Tx

nilotinib + cilostazol

monitor bleeding s/sx; decr. cilostazol dose to 50 mg bid: combo may incr. cilostazol levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• cimetidine
Nilceya (nilotinib)

+

cimetidine

1 interaction

Monitor/Modify Tx

nilotinib + cimetidine

give nilotinib 2h before or 10h after cimetidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• cinacalcet
Nilceya (nilotinib)

+

cinacalcet

1 interaction

Monitor/Modify Tx

nilotinib + cinacalcet

monitor calcium, ECG, bleeding s/sx: combo may incr. risk of severe hypocalcemia (incl. life-threatening), QT prolongation, cardiac arrhythmias, seizures, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ciprofloxacin
Nilceya (nilotinib)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

nilotinib + ciprofloxacin

monitor ECG, electrolytes, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• cisplatin
Nilceya (nilotinib)

+

cisplatin

1 interaction

Monitor/Modify Tx

nilotinib + cisplatin

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, tetany, hyponatremia (additive effects)

• clomipramine
Nilceya (nilotinib)

+

clomipramine

1 interaction

Monitor/Modify Tx

nilotinib + clomipramine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• clonazepam
Nilceya (nilotinib)

+

clonazepam

1 interaction

Monitor/Modify Tx

nilotinib + clonazepam

monitor resp. rate: combo may incr. clonazepam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• clopidogrel
Nilceya (nilotinib)

+

clopidogrel

1 interaction

Monitor/Modify Tx

nilotinib + clopidogrel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• clozapine
Nilceya (nilotinib)

+

clozapine

2 interactions

Monitor/Modify Tx

nilotinib + clozapine

monitor CBC, ECG, BP, HR, electrolytes; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• collagenase clostridium histolyticum
Nilceya (nilotinib)

+

collagenase clostridium histolyticum

1 interaction

Monitor/Modify Tx

nilotinib + collagenase clostridium histolyticum

monitor injection site bleeding s/sx: combo may incr. risk of localized bleeding, incl. severe (additive effects)

• copanlisib
Nilceya (nilotinib)

+

copanlisib

1 interaction

Monitor/Modify Tx

nilotinib + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• corticotropin
Nilceya (nilotinib)

+

corticotropin

1 interaction

Monitor/Modify Tx

nilotinib + corticotropin

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• cortisone
Nilceya (nilotinib)

+

cortisone

1 interaction

Monitor/Modify Tx

nilotinib + cortisone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• COVID-19 vaccine
Nilceya (nilotinib)

+

COVID-19 vaccine

1 interaction

Monitor/Modify Tx

nilotinib + COVID-19 vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• cyclophosphamide
Nilceya (nilotinib)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

nilotinib + cyclophosphamide

monitor CBC, sodium: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of myelosuppression, hyponatremia, incl. life-threatening (hepatic metab. possibly inhibited, decr. conversion to active metabolite; additive effects)

• cyclosporine
Nilceya (nilotinib)

+

cyclosporine

2 interactions

Monitor/Modify Tx

nilotinib + cyclosporine

monitor cyclosporine levels, renal fxn, ECG, CBC, potassium: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hyperkalemia, serious infection, nephrotoxicity, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• dabigatran
Nilceya (nilotinib)

+

dabigatran

1 interaction

Monitor/Modify Tx

nilotinib + dabigatran

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• dalteparin
Nilceya (nilotinib)

+

dalteparin

1 interaction

Monitor/Modify Tx

nilotinib + dalteparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• danazol
Nilceya (nilotinib)

+

danazol

1 interaction

Monitor/Modify Tx

nilotinib + danazol

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• danshen
Nilceya (nilotinib)

+

danshen

2 interactions

Monitor/Modify Tx

nilotinib + danshen

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• dapsone
Nilceya (nilotinib)

+

dapsone

1 interaction

Monitor/Modify Tx

nilotinib + dapsone

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• daridorexant
Nilceya (nilotinib)

+

daridorexant

1 interaction

Monitor/Modify Tx

nilotinib + daridorexant

adjust max daridorexant dose to 25 mg/day: combo may incr. daridorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• darunavir
Nilceya (nilotinib)

+

darunavir

2 interactions

Monitor/Modify Tx

nilotinib + darunavir

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dasatinib
Nilceya (nilotinib)

+

dasatinib

1 interaction

Monitor/Modify Tx

nilotinib + dasatinib

monitor ECG, electrolytes, CBC, bleeding s/sx: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• decitabine
Nilceya (nilotinib)

+

decitabine

1 interaction

Monitor/Modify Tx

nilotinib + decitabine

monitor potassium w/ IV decitabine use: combo may alter serum potassium levels (additive effects)

• deferasirox
Nilceya (nilotinib)

+

deferasirox

1 interaction

Monitor/Modify Tx

nilotinib + deferasirox

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• defibrotide
Nilceya (nilotinib)

+

defibrotide

2 interactions

Monitor/Modify Tx

nilotinib + defibrotide

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• denosumab
Nilceya (nilotinib)

+

denosumab

1 interaction

Monitor/Modify Tx

nilotinib + denosumab

monitor calcium: combo may incr. risk of severe hypocalcemia, incl. life-threatening (additive effects)

• desmopressin
Nilceya (nilotinib)

+

desmopressin

1 interaction

Monitor/Modify Tx

nilotinib + desmopressin

monitor sodium: combo may incr. risk of hyponatremia, incl. life-threatening (additive effects)

• desvenlafaxine
Nilceya (nilotinib)

+

desvenlafaxine

1 interaction

Monitor/Modify Tx

nilotinib + desvenlafaxine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• deuruxolitinib
Nilceya (nilotinib)

+

deuruxolitinib

1 interaction

Monitor/Modify Tx

nilotinib + deuruxolitinib

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, serious infection, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• deutetrabenazine
Nilceya (nilotinib)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

nilotinib + deutetrabenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dexamethasone
Nilceya (nilotinib)

+

dexamethasone

1 interaction

Monitor/Modify Tx

nilotinib + dexamethasone

monitor potassium, bleeding s/sx: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects incl. Cushing syndrome and adrenal suppression, serious infection, hypokalemia, GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• dichlorphenamide
Nilceya (nilotinib)

+

dichlorphenamide

1 interaction

Monitor/Modify Tx

nilotinib + dichlorphenamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• diclofenac
Nilceya (nilotinib)

+

diclofenac

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• diclofenac ophthalmic
Nilceya (nilotinib)

+

diclofenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• diclofenac topical
Nilceya (nilotinib)

+

diclofenac topical

1 interaction

Monitor/Modify Tx

nilotinib + diclofenac topical

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• diflunisal
Nilceya (nilotinib)

+

diflunisal

1 interaction

Monitor/Modify Tx

nilotinib + diflunisal

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• digoxin
Nilceya (nilotinib)

+

digoxin

1 interaction

Monitor/Modify Tx

nilotinib + digoxin

monitor electrolytes: combo may incr. risk of digoxin toxicity, cardiac arrhythmias (electrolyte abnormalities may incr. digoxin sensitivity)

• diltiazem
Nilceya (nilotinib)

+

diltiazem

1 interaction

Monitor/Modify Tx

nilotinib + diltiazem

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• dimethyl fumarate
Nilceya (nilotinib)

+

dimethyl fumarate

1 interaction

Monitor/Modify Tx

nilotinib + dimethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• dinutuximab
Nilceya (nilotinib)

+

dinutuximab

1 interaction

Monitor/Modify Tx

nilotinib + dinutuximab

monitor potassium, sodium: combo may incr. risk of hypokalemia, severe hyponatremia (additive effects)

• diosmin
Nilceya (nilotinib)

+

diosmin

1 interaction

Monitor/Modify Tx

nilotinib + diosmin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diphtheria/tetanus vaccine
Nilceya (nilotinib)

+

diphtheria/ tetanus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + diphtheria/ tetanus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• diphtheria/tetanus/pertussis vaccine
Nilceya (nilotinib)

+

diphtheria/ tetanus/ pertussis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + diphtheria/ tetanus/ pertussis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• dipyridamole
Nilceya (nilotinib)

+

dipyridamole

1 interaction

Monitor/Modify Tx

nilotinib + dipyridamole

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• diroximel fumarate
Nilceya (nilotinib)

+

diroximel fumarate

1 interaction

Monitor/Modify Tx

nilotinib + diroximel fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• docetaxel
Nilceya (nilotinib)

+

docetaxel

2 interactions

Monitor/Modify Tx

nilotinib + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• drospirenone (contraceptive)
Nilceya (nilotinib)

+

drospirenone (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + drospirenone (contraceptive)

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• drospirenone (hormone replacement)
Nilceya (nilotinib)

+

drospirenone (hormone replacement)

1 interaction

Monitor/Modify Tx

nilotinib + drospirenone (hormone replacement)

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• duloxetine
Nilceya (nilotinib)

+

duloxetine

1 interaction

Monitor/Modify Tx

nilotinib + duloxetine

monitor bleeding s/sx, sodium: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• duvelisib
Nilceya (nilotinib)

+

duvelisib

1 interaction

Monitor/Modify Tx

nilotinib + duvelisib

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ebola vaccine, live
Nilceya (nilotinib)

+

ebola vaccine, live

1 interaction

Monitor/Modify Tx

nilotinib + ebola vaccine, live

consider vaccinating at least 4wk before or 3mo after nilotinib tx: combo may result in inadequate vaccine response; may incr. risk of mild vesicular stomatitis virus infection (immunosuppressive effects, recombinant vaccine w/ vesicular stomatitis virus vector)

• edoxaban
Nilceya (nilotinib)

+

edoxaban

1 interaction

Monitor/Modify Tx

nilotinib + edoxaban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• efbemalenograstim alfa
Nilceya (nilotinib)

+

efbemalenograstim alfa

1 interaction

Monitor/Modify Tx

nilotinib + efbemalenograstim alfa

admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

• eflapegrastim (G-CSF)
Nilceya (nilotinib)

+

eflapegrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + eflapegrastim (G-CSF)

admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

• elexacaftor/tezacaftor/ivacaftor
Nilceya (nilotinib)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. dose by alternating one elexacaftor/tezacaftor/ivacaftor packet or one ivacaftor packet at each morning dose, no evening doses; 6 YO AND OLDER: decr. dose by alternating two elexacaftor/tezacaftor/ivacaftor tabs or one ivacaftor tab at each morning dose, no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• elivaldogene autotemcel
Nilceya (nilotinib)

+

elivaldogene autotemcel

2 interactions

Monitor/Modify Tx

nilotinib + elivaldogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

• emapalumab
Nilceya (nilotinib)

+

emapalumab

1 interaction

Monitor/Modify Tx

nilotinib + emapalumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• enalapril
Nilceya (nilotinib)

+

enalapril

1 interaction

Monitor/Modify Tx

nilotinib + enalapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• enalaprilat
Nilceya (nilotinib)

+

enalaprilat

1 interaction

Monitor/Modify Tx

nilotinib + enalaprilat

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• enoxaparin
Nilceya (nilotinib)

+

enoxaparin

1 interaction

Monitor/Modify Tx

nilotinib + enoxaparin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• epinephrine
Nilceya (nilotinib)

+

epinephrine

1 interaction

Monitor/Modify Tx

nilotinib + epinephrine

monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• eplerenone
Nilceya (nilotinib)

+

eplerenone

1 interaction

Monitor/Modify Tx

nilotinib + eplerenone

monitor potassium, Cr in 3-7 days after tx start; in post-MI CHF pts, max eplerenone dose 25 mg/day; in HTN pts, start eplerenone 25 mg qd, max dose 50 mg/day: combo may incr. eplerenone levels, risk of hyperkalemia, serious arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• epoprostenol
Nilceya (nilotinib)

+

epoprostenol

1 interaction

Monitor/Modify Tx

nilotinib + epoprostenol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• erlotinib
Nilceya (nilotinib)

+

erlotinib

1 interaction

Monitor/Modify Tx

nilotinib + erlotinib

monitor bleeding s/sx: combo may incr. erlotinib levels, risk of GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• eslicarbazepine acetate
Nilceya (nilotinib)

+

eslicarbazepine acetate

1 interaction

Monitor/Modify Tx

nilotinib + eslicarbazepine acetate

monitor sodium: combo may decr. nilotinib levels, efficacy; may incr. risk of hyponatremia (incl. life-threatening), seizures (hepatic metab. induced; additive effects)

• estazolam
Nilceya (nilotinib)

+

estazolam

1 interaction

Monitor/Modify Tx

nilotinib + estazolam

monitor resp. rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• estradiol (contraceptive)
Nilceya (nilotinib)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• ethacrynic acid
Nilceya (nilotinib)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

nilotinib + ethacrynic acid

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• ethanol
Nilceya (nilotinib)

+

ethanol

1 interaction

Monitor/Modify Tx

nilotinib + ethanol

monitor bleeding s/sx w/ orally ingested alcohol: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ethinyl estradiol (contraceptive)
Nilceya (nilotinib)

+

ethinyl estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

nilotinib + ethinyl estradiol (contraceptive)

monitor thrombosis s/sx, especially if oral ethinyl estradiol dose >35 mcg/day: combo may incr. ethinyl estradiol levels, risk of thromboembolism, other adverse effects (hepatic metab. inhibited)

• etodolac
Nilceya (nilotinib)

+

etodolac

1 interaction

Monitor/Modify Tx

nilotinib + etodolac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• evening primrose oil
Nilceya (nilotinib)

+

evening primrose oil

1 interaction

Monitor/Modify Tx

nilotinib + evening primrose oil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• everolimus
Nilceya (nilotinib)

+

everolimus

1 interaction

Monitor/Modify Tx

nilotinib + everolimus

BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA w/ TSC: if also combined w/ P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated, monitor CBC; otherwise, monitor CBC; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES: if also combined w/ P-gp inhibitor, monitor everolimus levels, CBC and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels, CBC; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• exagamglogene autotemcel
Nilceya (nilotinib)

+

exagamglogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + exagamglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• famotidine
Nilceya (nilotinib)

+

famotidine

1 interaction

Monitor/Modify Tx

nilotinib + famotidine

give nilotinib 2h before or 10h after famotidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• febuxostat
Nilceya (nilotinib)

+

febuxostat

1 interaction

Monitor/Modify Tx

nilotinib + febuxostat

monitor uric acid levels: combo may decr. febuxostat efficacy (antagonistic effects)

• fedratinib
Nilceya (nilotinib)

+

fedratinib

1 interaction

Monitor/Modify Tx

nilotinib + fedratinib

if fedratinib also combined w/ CYP2C19 inhibitor, monitor CBC, LFTs, ECG; otherwise, monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• felodipine
Nilceya (nilotinib)

+

felodipine

1 interaction

Monitor/Modify Tx

nilotinib + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metab. inhibited)

• fenoprofen
Nilceya (nilotinib)

+

fenoprofen

2 interactions

Monitor/Modify Tx

nilotinib + fenoprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• fenugreek
Nilceya (nilotinib)

+

fenugreek

1 interaction

Monitor/Modify Tx

nilotinib + fenugreek

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• filgrastim (G-CSF)
Nilceya (nilotinib)

+

filgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + filgrastim (G-CSF)

admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

• finerenone
Nilceya (nilotinib)

+

finerenone

1 interaction

Monitor/Modify Tx

nilotinib + finerenone

monitor potassium: combo may incr. finerenone levels, risk of hyperkalemia, other adverse effects (hepatic metab. inhibited, additive effects)

• flucytosine
Nilceya (nilotinib)

+

flucytosine

2 interactions

Monitor/Modify Tx

nilotinib + flucytosine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fludrocortisone
Nilceya (nilotinib)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

nilotinib + fludrocortisone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• fluphenazine
Nilceya (nilotinib)

+

fluphenazine

1 interaction

Monitor/Modify Tx

nilotinib + fluphenazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• flurbiprofen
Nilceya (nilotinib)

+

flurbiprofen

1 interaction

Monitor/Modify Tx

nilotinib + flurbiprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• fluvoxamine
Nilceya (nilotinib)

+

fluvoxamine

1 interaction

Monitor/Modify Tx

nilotinib + fluvoxamine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• fondaparinux
Nilceya (nilotinib)

+

fondaparinux

1 interaction

Monitor/Modify Tx

nilotinib + fondaparinux

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• formoterol inhaled
Nilceya (nilotinib)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + formoterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• fosamprenavir
Nilceya (nilotinib)

+

fosamprenavir

1 interaction

Monitor/Modify Tx

nilotinib + fosamprenavir

monitor ECG, CBC: combo may incr. or decr. nilotinib levels, incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects or decr. efficacy (hepatic metab. altered)

• fosinopril
Nilceya (nilotinib)

+

fosinopril

1 interaction

Monitor/Modify Tx

nilotinib + fosinopril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• fostamatinib
Nilceya (nilotinib)

+

fostamatinib

1 interaction

Monitor/Modify Tx

nilotinib + fostamatinib

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• fostemsavir
Nilceya (nilotinib)

+

fostemsavir

1 interaction

Monitor/Modify Tx

nilotinib + fostemsavir

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fruquintinib
Nilceya (nilotinib)

+

fruquintinib

1 interaction

Monitor/Modify Tx

nilotinib + fruquintinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• furosemide
Nilceya (nilotinib)

+

furosemide

1 interaction

Monitor/Modify Tx

nilotinib + furosemide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, tetany, hyponatremia (additive effects)

• futibatinib
Nilceya (nilotinib)

+

futibatinib

1 interaction

Monitor/Modify Tx

nilotinib + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metab. inhibited)

• galantamine
Nilceya (nilotinib)

+

galantamine

1 interaction

Monitor/Modify Tx

nilotinib + galantamine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• garlic
Nilceya (nilotinib)

+

garlic

1 interaction

Monitor/Modify Tx

nilotinib + garlic

monitor bleeding s/sx, especially w/ supplemental garlic; dietary intake OK: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• gefitinib
Nilceya (nilotinib)

+

gefitinib

1 interaction

Monitor/Modify Tx

nilotinib + gefitinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• gentamicin
Nilceya (nilotinib)

+

gentamicin

1 interaction

Monitor/Modify Tx

nilotinib + gentamicin

monitor calcium: combo may incr. risk of hypocalcemia, tetany (additive effects)

• gepirone
Nilceya (nilotinib)

+

gepirone

1 interaction

Monitor/Modify Tx

nilotinib + gepirone

monitor ECG, electrolytes; decr. gepirone dose 50%: combo may incr. gepirone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• ginkgo
Nilceya (nilotinib)

+

ginkgo

1 interaction

Monitor/Modify Tx

nilotinib + ginkgo

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• granisetron
Nilceya (nilotinib)

+

granisetron

1 interaction

Monitor/Modify Tx

nilotinib + granisetron

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• guanfacine
Nilceya (nilotinib)

+

guanfacine

1 interaction

Monitor/Modify Tx

nilotinib + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metab. inhibited)

• Haemophilus b vaccine
Nilceya (nilotinib)

+

Haemophilus b vaccine

1 interaction

Monitor/Modify Tx

nilotinib + Haemophilus b vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• heparin
Nilceya (nilotinib)

+

heparin

1 interaction

Monitor/Modify Tx

nilotinib + heparin

monitor bleeding s/sx, potassium: combo may incr. risk of GI or other bleeding (incl. life-threatening), hyperkalemia (additive effects)

• hepatitis A vaccine
Nilceya (nilotinib)

+

hepatitis A vaccine

1 interaction

Monitor/Modify Tx

nilotinib + hepatitis A vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hepatitis B vaccine
Nilceya (nilotinib)

+

hepatitis B vaccine

1 interaction

Monitor/Modify Tx

nilotinib + hepatitis B vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• human papillomavirus vaccine
Nilceya (nilotinib)

+

human papillomavirus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + human papillomavirus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• hydroxyurea
Nilceya (nilotinib)

+

hydroxyurea

1 interaction

Monitor/Modify Tx

nilotinib + hydroxyurea

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ibandronate
Nilceya (nilotinib)

+

ibandronate

1 interaction

Monitor/Modify Tx

nilotinib + ibandronate

monitor calcium, bleeding s/sx if oral ibandronate use: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ibrutinib
Nilceya (nilotinib)

+

ibrutinib

1 interaction

Monitor/Modify Tx

nilotinib + ibrutinib

monitor bleeding s/sx; B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• ibuprofen
Nilceya (nilotinib)

+

ibuprofen

1 interaction

Monitor/Modify Tx

nilotinib + ibuprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ibuprofen lysine
Nilceya (nilotinib)

+

ibuprofen lysine

1 interaction

Monitor/Modify Tx

nilotinib + ibuprofen lysine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• icosapent ethyl
Nilceya (nilotinib)

+

icosapent ethyl

1 interaction

Monitor/Modify Tx

nilotinib + icosapent ethyl

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ifosfamide
Nilceya (nilotinib)

+

ifosfamide

1 interaction

Monitor/Modify Tx

nilotinib + ifosfamide

monitor sodium: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of hyponatremia (hepatic metab. altered, incr. or decr. active metabolite formation; additive effects)

• iloprost inhaled
Nilceya (nilotinib)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

nilotinib + iloprost inhaled

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• imatinib
Nilceya (nilotinib)

+

imatinib

1 interaction

Monitor/Modify Tx

nilotinib + imatinib

monitor ECG, CBC, bleeding s/sx: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• indapamide
Nilceya (nilotinib)

+

indapamide

1 interaction

Monitor/Modify Tx

nilotinib + indapamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, severe hyponatremia (additive effects)

• indomethacin
Nilceya (nilotinib)

+

indomethacin

1 interaction

Monitor/Modify Tx

nilotinib + indomethacin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• influenza H5N1 vaccine
Nilceya (nilotinib)

+

influenza H5N1 vaccine

1 interaction

Monitor/Modify Tx

nilotinib + influenza H5N1 vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• influenza vaccine
Nilceya (nilotinib)

+

influenza vaccine

1 interaction

Monitor/Modify Tx

nilotinib + influenza vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider vaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• insulin
Nilceya (nilotinib)

+

insulin

1 interaction

Monitor/Modify Tx

nilotinib + insulin

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• interferon beta 1a
Nilceya (nilotinib)

+

interferon beta 1a

2 interactions

Monitor/Modify Tx

nilotinib + interferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon beta 1b
Nilceya (nilotinib)

+

interferon beta 1b

1 interaction

Monitor/Modify Tx

nilotinib + interferon beta 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• interferon gamma 1b
Nilceya (nilotinib)

+

interferon gamma 1b

2 interactions

Monitor/Modify Tx

nilotinib + interferon gamma 1b

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• irbesartan
Nilceya (nilotinib)

+

irbesartan

2 interactions

Monitor/Modify Tx

nilotinib + irbesartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• irinotecan
Nilceya (nilotinib)

+

irinotecan

2 interactions

Monitor/Modify Tx

nilotinib + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metab. inhibited)

• isavuconazonium
Nilceya (nilotinib)

+

isavuconazonium

2 interactions

Monitor/Modify Tx

nilotinib + isavuconazonium

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• isoproterenol
Nilceya (nilotinib)

+

isoproterenol

1 interaction

Monitor/Modify Tx

nilotinib + isoproterenol

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• Japanese encephalitis vaccine
Nilceya (nilotinib)

+

Japanese encephalitis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + Japanese encephalitis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ketoprofen
Nilceya (nilotinib)

+

ketoprofen

1 interaction

Monitor/Modify Tx

nilotinib + ketoprofen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ketorolac
Nilceya (nilotinib)

+

ketorolac

1 interaction

Monitor/Modify Tx

nilotinib + ketorolac

monitor bleeding s/sx, potassium: combo may incr. risk of GI ulceration, perforation, bleeding (incl. life-threatening), hyperkalemia (additive effects)

• ketorolac ophthalmic
Nilceya (nilotinib)

+

ketorolac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + ketorolac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• landiolol
Nilceya (nilotinib)

+

landiolol

1 interaction

Monitor/Modify Tx

nilotinib + landiolol

monitor potassium, especially if renal impairment: combo may incr. risk of hyperkalemia (additive effects)

• lanthanum
Nilceya (nilotinib)

+

lanthanum

1 interaction

Monitor/Modify Tx

nilotinib + lanthanum

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• lapatinib
Nilceya (nilotinib)

+

lapatinib

1 interaction

Monitor/Modify Tx

nilotinib + lapatinib

monitor ECG, electrolytes; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• leflunomide
Nilceya (nilotinib)

+

leflunomide

1 interaction

Monitor/Modify Tx

nilotinib + leflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• lenacapavir
Nilceya (nilotinib)

+

lenacapavir

1 interaction

Monitor/Modify Tx

nilotinib + lenacapavir

monitor ECG, CBC during and x9mo after lenacapavir tx: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• lenalidomide
Nilceya (nilotinib)

+

lenalidomide

1 interaction

Monitor/Modify Tx

nilotinib + lenalidomide

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• lenvatinib
Nilceya (nilotinib)

+

lenvatinib

1 interaction

Monitor/Modify Tx

nilotinib + lenvatinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypocalcemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• letermovir
Nilceya (nilotinib)

+

letermovir

1 interaction

Monitor/Modify Tx

nilotinib + letermovir

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• levalbuterol inhaled
Nilceya (nilotinib)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + levalbuterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• levomilnacipran
Nilceya (nilotinib)

+

levomilnacipran

1 interaction

Monitor/Modify Tx

nilotinib + levomilnacipran

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• licorice
Nilceya (nilotinib)

+

licorice

1 interaction

Monitor/Modify Tx

nilotinib + licorice

monitor potassium w/ large amounts of licorice: combo may incr. risk of hypokalemia (additive effects)

• lidocaine
Nilceya (nilotinib)

+

lidocaine

1 interaction

Monitor/Modify Tx

nilotinib + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher w/ continuous infusion or higher doses for local anesthesia (hepatic metab. inhibited)

• lifileucel
Nilceya (nilotinib)

+

lifileucel

1 interaction

Monitor/Modify Tx

nilotinib + lifileucel

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• linezolid
Nilceya (nilotinib)

+

linezolid

1 interaction

Monitor/Modify Tx

nilotinib + linezolid

monitor sodium, CBC: combo may incr. risk of hyponatremia, myelosuppression (additive effects)

• losartan
Nilceya (nilotinib)

+

losartan

1 interaction

Monitor/Modify Tx

nilotinib + losartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• lovotibeglogene autotemcel
Nilceya (nilotinib)

+

lovotibeglogene autotemcel

1 interaction

Monitor/Modify Tx

nilotinib + lovotibeglogene autotemcel

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

• lumateperone
Nilceya (nilotinib)

+

lumateperone

1 interaction

Monitor/Modify Tx

nilotinib + lumateperone

monitor ECG, electrolytes, CBC; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• lurasidone
Nilceya (nilotinib)

+

lurasidone

1 interaction

Monitor/Modify Tx

nilotinib + lurasidone

monitor ECG, electrolytes; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Nilceya (nilotinib)

+

lymphocyte immune globulin, anti-thymocyte globulin

1 interaction

Monitor/Modify Tx

nilotinib + lymphocyte immune globulin, anti-thymocyte globulin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• magnesium carbonate
Nilceya (nilotinib)

+

magnesium carbonate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium carbonate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium citrate
Nilceya (nilotinib)

+

magnesium citrate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium citrate

monitor sodium, potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• magnesium hydroxide
Nilceya (nilotinib)

+

magnesium hydroxide

1 interaction

Monitor/Modify Tx

nilotinib + magnesium hydroxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium oxide
Nilceya (nilotinib)

+

magnesium oxide

1 interaction

Monitor/Modify Tx

nilotinib + magnesium oxide

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• magnesium salicylate
Nilceya (nilotinib)

+

magnesium salicylate

1 interaction

Monitor/Modify Tx

nilotinib + magnesium salicylate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• mannitol
Nilceya (nilotinib)

+

mannitol

1 interaction

Monitor/Modify Tx

nilotinib + mannitol

monitor sodium, potassium, ECG: combo may incr. risk of hyponatremia (incl. life-threatening), seizures, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• mavorixafor
Nilceya (nilotinib)

+

mavorixafor

1 interaction

Monitor/Modify Tx

nilotinib + mavorixafor

monitor ECG, electrolytes: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• meclofenamate
Nilceya (nilotinib)

+

meclofenamate

1 interaction

Monitor/Modify Tx

nilotinib + meclofenamate

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• mefenamic acid
Nilceya (nilotinib)

+

mefenamic acid

1 interaction

Monitor/Modify Tx

nilotinib + mefenamic acid

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• mefloquine
Nilceya (nilotinib)

+

mefloquine

2 interactions

Monitor/Modify Tx

nilotinib + mefloquine

monitor ECG, electrolytes: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• meloxicam
Nilceya (nilotinib)

+

meloxicam

1 interaction

Monitor/Modify Tx

nilotinib + meloxicam

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• meningococcal vaccine
Nilceya (nilotinib)

+

meningococcal vaccine

1 interaction

Monitor/Modify Tx

nilotinib + meningococcal vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• mercaptopurine
Nilceya (nilotinib)

+

mercaptopurine

1 interaction

Monitor/Modify Tx

nilotinib + mercaptopurine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine
Nilceya (nilotinib)

+

mesalamine

1 interaction

Monitor/Modify Tx

nilotinib + mesalamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• mesalamine rectal
Nilceya (nilotinib)

+

mesalamine rectal

1 interaction

Monitor/Modify Tx

nilotinib + mesalamine rectal

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• methazolamide
Nilceya (nilotinib)

+

methazolamide

1 interaction

Monitor/Modify Tx

nilotinib + methazolamide

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia (additive effects)

• methotrexate
Nilceya (nilotinib)

+

methotrexate

1 interaction

Monitor/Modify Tx

nilotinib + methotrexate

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• metronidazole
Nilceya (nilotinib)

+

metronidazole

2 interactions

Monitor/Modify Tx

nilotinib + metronidazole

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Nilceya (nilotinib)

+

midostaurin

1 interaction

Monitor/Modify Tx

nilotinib + midostaurin

monitor ECG, electrolytes, CBC: combo may incr. midostaurin levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• milnacipran
Nilceya (nilotinib)

+

milnacipran

1 interaction

Monitor/Modify Tx

nilotinib + milnacipran

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• mirtazapine
Nilceya (nilotinib)

+

mirtazapine

1 interaction

Monitor/Modify Tx

nilotinib + mirtazapine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia (additive effects)

• moexipril
Nilceya (nilotinib)

+

moexipril

1 interaction

Monitor/Modify Tx

nilotinib + moexipril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• monomethyl fumarate
Nilceya (nilotinib)

+

monomethyl fumarate

1 interaction

Monitor/Modify Tx

nilotinib + monomethyl fumarate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• motixafortide
Nilceya (nilotinib)

+

motixafortide

1 interaction

Monitor/Modify Tx

nilotinib + motixafortide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• mycophenolate mofetil
Nilceya (nilotinib)

+

mycophenolate mofetil

1 interaction

Monitor/Modify Tx

nilotinib + mycophenolate mofetil

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• mycophenolic acid
Nilceya (nilotinib)

+

mycophenolic acid

1 interaction

Monitor/Modify Tx

nilotinib + mycophenolic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• nabumetone
Nilceya (nilotinib)

+

nabumetone

2 interactions

Monitor/Modify Tx

nilotinib + nabumetone

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• naproxen
Nilceya (nilotinib)

+

naproxen

2 interactions

Monitor/Modify Tx

nilotinib + naproxen

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• nattokinase
Nilceya (nilotinib)

+

nattokinase

1 interaction

Monitor/Modify Tx

nilotinib + nattokinase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• necitumumab
Nilceya (nilotinib)

+

necitumumab

1 interaction

Monitor/Modify Tx

nilotinib + necitumumab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• nepafenac ophthalmic
Nilceya (nilotinib)

+

nepafenac ophthalmic

1 interaction

Monitor/Modify Tx

nilotinib + nepafenac ophthalmic

monitor bleeding s/sx: combo may incr. risk of postop ocular bleeding (additive effects)

• netupitant
Nilceya (nilotinib)

+

netupitant

1 interaction

Monitor/Modify Tx

nilotinib + netupitant

monitor ECG, CBC: combo may incr. nilotinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metab. inhibited)

• niacin (vitamin B3)
Nilceya (nilotinib)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

nilotinib + niacin (vitamin B3)

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• nifedipine
Nilceya (nilotinib)

+

nifedipine

1 interaction

Monitor/Modify Tx

nilotinib + nifedipine

monitor BP, consider lowest nifedipine start dose: combo may incr. nifedipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nimodipine
Nilceya (nilotinib)

+

nimodipine

1 interaction

Monitor/Modify Tx

nilotinib + nimodipine

monitor BP: combo may incr. nimodipine levels, risk of hypotension, other adverse effects (hepatic metab. inhibited)

• nintedanib
Nilceya (nilotinib)

+

nintedanib

1 interaction

Monitor/Modify Tx

nilotinib + nintedanib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• nizatidine
Nilceya (nilotinib)

+

nizatidine

1 interaction

Monitor/Modify Tx

nilotinib + nizatidine

give nilotinib 2h before or 10h after nizatidine: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• nortriptyline
Nilceya (nilotinib)

+

nortriptyline

1 interaction

Monitor/Modify Tx

nilotinib + nortriptyline

monitor nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metab. inhibited)

• nusinersen
Nilceya (nilotinib)

+

nusinersen

1 interaction

Monitor/Modify Tx

nilotinib + nusinersen

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• ofloxacin
Nilceya (nilotinib)

+

ofloxacin

1 interaction

Monitor/Modify Tx

nilotinib + ofloxacin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olodaterol inhaled
Nilceya (nilotinib)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + olodaterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• olsalazine
Nilceya (nilotinib)

+

olsalazine

1 interaction

Monitor/Modify Tx

nilotinib + olsalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• omega-3-acid
Nilceya (nilotinib)

+

omega-3-acid

1 interaction

Monitor/Modify Tx

nilotinib + omega-3-acid

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• osilodrostat
Nilceya (nilotinib)

+

osilodrostat

1 interaction

Monitor/Modify Tx

nilotinib + osilodrostat

monitor ECG, electrolytes: combo may incr. osilodrostat levels, risk of QT prolongation, cardiac arrhythmias, hypokalemia, other adverse effects (hepatic metab. inhibited, additive effects)

• oxaprozin
Nilceya (nilotinib)

+

oxaprozin

1 interaction

Monitor/Modify Tx

nilotinib + oxaprozin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• oxcarbazepine
Nilceya (nilotinib)

+

oxcarbazepine

1 interaction

Monitor/Modify Tx

nilotinib + oxcarbazepine

monitor sodium: combo may decr. nilotinib levels, efficacy; may incr. risk of hyponatremia, seizures (hepatic metab. induced; additive effects)

• oxytocin
Nilceya (nilotinib)

+

oxytocin

1 interaction

Monitor/Modify Tx

nilotinib + oxytocin

monitor sodium: combo may incr. risk of hyponatremia (additive effects)

• palbociclib
Nilceya (nilotinib)

+

palbociclib

1 interaction

Monitor/Modify Tx

nilotinib + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metab. inhibited)

• palopegteriparatide
Nilceya (nilotinib)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

nilotinib + palopegteriparatide

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• pamidronate
Nilceya (nilotinib)

+

pamidronate

1 interaction

Monitor/Modify Tx

nilotinib + pamidronate

monitor potassium, calcium: combo may incr. risk of hypocalcemia, hypokalemia (additive effects)

• panitumumab
Nilceya (nilotinib)

+

panitumumab

1 interaction

Monitor/Modify Tx

nilotinib + panitumumab

monitor potassium, calcium: combo may incr. risk of hypokalemia, hypocalcemia (additive effects)

• paroxetine
Nilceya (nilotinib)

+

paroxetine

1 interaction

Monitor/Modify Tx

nilotinib + paroxetine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• pegaspargase
Nilceya (nilotinib)

+

pegaspargase

1 interaction

Monitor/Modify Tx

nilotinib + pegaspargase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pegfilgrastim (G-CSF)
Nilceya (nilotinib)

+

pegfilgrastim (G-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + pegfilgrastim (G-CSF)

admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

• peginterferon alfa 2a
Nilceya (nilotinib)

+

peginterferon alfa 2a

1 interaction

Monitor/Modify Tx

nilotinib + peginterferon alfa 2a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• peginterferon beta 1a
Nilceya (nilotinib)

+

peginterferon beta 1a

1 interaction

Monitor/Modify Tx

nilotinib + peginterferon beta 1a

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• pegloticase
Nilceya (nilotinib)

+

pegloticase

1 interaction

Monitor/Modify Tx

nilotinib + pegloticase

monitor uric acid levels: combo may decr. pegloticase efficacy (antagonistic effects)

• penicillin G
Nilceya (nilotinib)

+

penicillin G

1 interaction

Monitor/Modify Tx

nilotinib + penicillin G

monitor bleeding s/sx, especially w/ large penicillin G doses and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pentosan polysulfate sodium
Nilceya (nilotinib)

+

pentosan polysulfate sodium

2 interactions

Monitor/Modify Tx

nilotinib + pentosan polysulfate sodium

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• pentoxifylline
Nilceya (nilotinib)

+

pentoxifylline

2 interactions

Monitor/Modify Tx

nilotinib + pentoxifylline

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• piperacillin
Nilceya (nilotinib)

+

piperacillin

1 interaction

Monitor/Modify Tx

nilotinib + piperacillin

monitor bleeding s/sx, especially w/ prolonged piperacillin tx and/or concomitant renal impairment: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• piroxicam
Nilceya (nilotinib)

+

piroxicam

1 interaction

Monitor/Modify Tx

nilotinib + piroxicam

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• pirtobrutinib
Nilceya (nilotinib)

+

pirtobrutinib

2 interactions

Monitor/Modify Tx

nilotinib + pirtobrutinib

monitor CBC, bleeding s/sx: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• polyethylene glycol/electrolytes
Nilceya (nilotinib)

+

polyethylene glycol/ electrolytes

1 interaction

Monitor/Modify Tx

nilotinib + polyethylene glycol/ electrolytes

monitor sodium, potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• ponatinib
Nilceya (nilotinib)

+

ponatinib

1 interaction

Monitor/Modify Tx

nilotinib + ponatinib

monitor CBC, bleeding s/sx: combo may incr. ponatinib levels, risk of serious infection, myelosuppression, GI ulceration, perforation, bleeding, (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• potassium bicarbonate
Nilceya (nilotinib)

+

potassium bicarbonate

1 interaction

Monitor/Modify Tx

nilotinib + potassium bicarbonate

monitor potassium, ECG: combo may incr. risk of severe hyperkalemia, cardiac arrest (additive effects)

• prednisolone
Nilceya (nilotinib)

+

prednisolone

1 interaction

Monitor/Modify Tx

nilotinib + prednisolone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• probenecid
Nilceya (nilotinib)

+

probenecid

2 interactions

Monitor/Modify Tx

nilotinib + probenecid

monitor uric acid levels: combo may decr. probenecid efficacy (antagonistic effects)

• proguanil
Nilceya (nilotinib)

+

proguanil

1 interaction

Monitor/Modify Tx

nilotinib + proguanil

monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

• promethazine
Nilceya (nilotinib)

+

promethazine

1 interaction

Monitor/Modify Tx

nilotinib + promethazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pyridostigmine
Nilceya (nilotinib)

+

pyridostigmine

1 interaction

Monitor/Modify Tx

nilotinib + pyridostigmine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• pyrimethamine
Nilceya (nilotinib)

+

pyrimethamine

1 interaction

Monitor/Modify Tx

nilotinib + pyrimethamine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• quinapril
Nilceya (nilotinib)

+

quinapril

1 interaction

Monitor/Modify Tx

nilotinib + quinapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• ramipril
Nilceya (nilotinib)

+

ramipril

1 interaction

Monitor/Modify Tx

nilotinib + ramipril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• ramucirumab
Nilceya (nilotinib)

+

ramucirumab

1 interaction

Monitor/Modify Tx

nilotinib + ramucirumab

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• ranibizumab
Nilceya (nilotinib)

+

ranibizumab

1 interaction

Monitor/Modify Tx

nilotinib + ranibizumab

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ranolazine
Nilceya (nilotinib)

+

ranolazine

1 interaction

Monitor/Modify Tx

nilotinib + ranolazine

monitor ECG, electrolytes; adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• rasburicase
Nilceya (nilotinib)

+

rasburicase

1 interaction

Monitor/Modify Tx

nilotinib + rasburicase

monitor uric acid levels: combo may decr. rasburicase efficacy (antagonistic effects)

• red yeast rice
Nilceya (nilotinib)

+

red yeast rice

1 interaction

Monitor/Modify Tx

nilotinib + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metab. inhibited, red yeast rice contains varying amounts of lovastatin)

• respiratory syncytial virus vaccine
Nilceya (nilotinib)

+

respiratory syncytial virus vaccine

1 interaction

Monitor/Modify Tx

nilotinib + respiratory syncytial virus vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• resveratrol
Nilceya (nilotinib)

+

resveratrol

1 interaction

Monitor/Modify Tx

nilotinib + resveratrol

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• reteplase
Nilceya (nilotinib)

+

reteplase

1 interaction

Monitor/Modify Tx

nilotinib + reteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• revakinagene taroretcel
Nilceya (nilotinib)

+

revakinagene taroretcel

1 interaction

Monitor/Modify Tx

nilotinib + revakinagene taroretcel

monitor bleeding s/sx: combo may incr. risk of ocular hemorrhage (additive effects)

• ribavirin
Nilceya (nilotinib)

+

ribavirin

1 interaction

Monitor/Modify Tx

nilotinib + ribavirin

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rimegepant
Nilceya (nilotinib)

+

rimegepant

1 interaction

Monitor/Modify Tx

nilotinib + rimegepant

separate rimegepant doses by at least 48h: combo may incr. rimegepant levels, risk of adverse effects (hepatic metab. inhibited)

• riociguat
Nilceya (nilotinib)

+

riociguat

1 interaction

Monitor/Modify Tx

nilotinib + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metab. inhibited)

• risedronate
Nilceya (nilotinib)

+

risedronate

1 interaction

Monitor/Modify Tx

nilotinib + risedronate

monitor calcium, bleeding s/sx: combo may incr. risk of hypocalcemia, upper GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• rituximab
Nilceya (nilotinib)

+

rituximab

1 interaction

Monitor/Modify Tx

nilotinib + rituximab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• rivastigmine
Nilceya (nilotinib)

+

rivastigmine

1 interaction

Monitor/Modify Tx

nilotinib + rivastigmine

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• romosozumab
Nilceya (nilotinib)

+

romosozumab

1 interaction

Monitor/Modify Tx

nilotinib + romosozumab

monitor calcium, especially w/ concomitant renal impairment: combo may incr. risk of hypocalcemia (additive effects)

• ruxolitinib
Nilceya (nilotinib)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

nilotinib + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited)

• ruxolitinib topical
Nilceya (nilotinib)

+

ruxolitinib topical

1 interaction

Monitor/Modify Tx

nilotinib + ruxolitinib topical

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• sacituzumab govitecan
Nilceya (nilotinib)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

nilotinib + sacituzumab govitecan

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• salmeterol inhaled
Nilceya (nilotinib)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + salmeterol inhaled

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• salsalate
Nilceya (nilotinib)

+

salsalate

1 interaction

Monitor/Modify Tx

nilotinib + salsalate

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• sargramostim (GM-CSF)
Nilceya (nilotinib)

+

sargramostim (GM-CSF)

1 interaction

Monitor/Modify Tx

nilotinib + sargramostim (GM-CSF)

admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

• sarilumab
Nilceya (nilotinib)

+

sarilumab

2 interactions

Monitor/Modify Tx

nilotinib + sarilumab

monitor CBC: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Nilceya (nilotinib)

+

satralizumab

1 interaction

Monitor/Modify Tx

nilotinib + satralizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• saw palmetto
Nilceya (nilotinib)

+

saw palmetto

1 interaction

Monitor/Modify Tx

nilotinib + saw palmetto

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sebetralstat
Nilceya (nilotinib)

+

sebetralstat

1 interaction

Monitor/Modify Tx

nilotinib + sebetralstat

monitor ECG, electrolytes; decr. sebetralstat dose to 300 mg, may give second 300 mg dose at least 3h after first dose if needed: combo may incr. sebetralstat levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metab. inhibited, additive effects)

• selinexor
Nilceya (nilotinib)

+

selinexor

1 interaction

Monitor/Modify Tx

nilotinib + selinexor

monitor potassium, sodium: combo may incr. risk of hypokalemia, hyponatremia, incl. life-threatening (additive effects)

• sepiapterin
Nilceya (nilotinib)

+

sepiapterin

1 interaction

Monitor/Modify Tx

nilotinib + sepiapterin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• sirolimus
Nilceya (nilotinib)

+

sirolimus

1 interaction

Monitor/Modify Tx

nilotinib + sirolimus

monitor sirolimus levels, CBC: combo may incr. sirolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• sirolimus albumin-bound
Nilceya (nilotinib)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

nilotinib + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, potassium, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), hypokalemia, other adverse effects (hepatic metab. inhibited, additive effects)

• smallpox/mpox vaccine, live
Nilceya (nilotinib)

+

smallpox/ mpox vaccine, live

1 interaction

Monitor/Modify Tx

nilotinib + smallpox/ mpox vaccine, live

consider vaccinating at least 4wk before or 3mo after nilotinib tx: combo may result in inadequate vaccine response (immunosuppressive effects)

• sodium benzoate
Nilceya (nilotinib)

+

sodium benzoate

1 interaction

Monitor/Modify Tx

nilotinib + sodium benzoate

monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

• sodium bicarbonate
Nilceya (nilotinib)

+

sodium bicarbonate

1 interaction

Monitor/Modify Tx

nilotinib + sodium bicarbonate

separate admin. w/ oral sodium bicarbonate by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium citrate
Nilceya (nilotinib)

+

sodium citrate

1 interaction

Monitor/Modify Tx

nilotinib + sodium citrate

separate admin. by at least 2h: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sodium phenylacetate
Nilceya (nilotinib)

+

sodium phenylacetate

1 interaction

Monitor/Modify Tx

nilotinib + sodium phenylacetate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium phenylbutyrate
Nilceya (nilotinib)

+

sodium phenylbutyrate

1 interaction

Monitor/Modify Tx

nilotinib + sodium phenylbutyrate

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• sodium polystyrene sulfonate
Nilceya (nilotinib)

+

sodium polystyrene sulfonate

1 interaction

Monitor/Modify Tx

nilotinib + sodium polystyrene sulfonate

monitor calcium, potassium, ECG: combo may incr. risk of hypocalcemia, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• sodium thiosulfate
Nilceya (nilotinib)

+

sodium thiosulfate

1 interaction

Monitor/Modify Tx

nilotinib + sodium thiosulfate

if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

• sodium zirconium cyclosilicate
Nilceya (nilotinib)

+

sodium zirconium cyclosilicate

1 interaction

Monitor/Modify Tx

nilotinib + sodium zirconium cyclosilicate

give nilotinib at least 2h before or 2h after sodium zirconium cyclosilicate: combo may decr. nilotinib levels, efficacy (absorption decreased at higher gastric pH)

• sotatercept
Nilceya (nilotinib)

+

sotatercept

1 interaction

Monitor/Modify Tx

nilotinib + sotatercept

monitor platelets, bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. severe or life-threatening (additive effects)

• sparsentan
Nilceya (nilotinib)

+

sparsentan

1 interaction

Monitor/Modify Tx

nilotinib + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (incl. orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• spironolactone
Nilceya (nilotinib)

+

spironolactone

1 interaction

Monitor/Modify Tx

nilotinib + spironolactone

monitor potassium, sodium: combo may incr. risk of severe hyperkalemia, hyponatremia (additive effects)

• stiripentol
Nilceya (nilotinib)

+

stiripentol

1 interaction

Monitor/Modify Tx

nilotinib + stiripentol

monitor CBC: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression (hepatic metab. possibly induced; additive effects)

• succimer
Nilceya (nilotinib)

+

succimer

1 interaction

Monitor/Modify Tx

nilotinib + succimer

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• succinylcholine
Nilceya (nilotinib)

+

succinylcholine

1 interaction

Monitor/Modify Tx

nilotinib + succinylcholine

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• sulfasalazine
Nilceya (nilotinib)

+

sulfasalazine

1 interaction

Monitor/Modify Tx

nilotinib + sulfasalazine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• sulfate bowel prep
Nilceya (nilotinib)

+

sulfate bowel prep

1 interaction

Monitor/Modify Tx

nilotinib + sulfate bowel prep

monitor sodium, potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias, hyponatremia, seizures (additive effects)

• sulindac
Nilceya (nilotinib)

+

sulindac

1 interaction

Monitor/Modify Tx

nilotinib + sulindac

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• sunitinib
Nilceya (nilotinib)

+

sunitinib

1 interaction

Monitor/Modify Tx

nilotinib + sunitinib

monitor ECG, electrolytes, bleeding s/sx: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• suvorexant
Nilceya (nilotinib)

+

suvorexant

1 interaction

Monitor/Modify Tx

nilotinib + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• suzetrigine
Nilceya (nilotinib)

+

suzetrigine

1 interaction

Monitor/Modify Tx

nilotinib + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• tadalafil
Nilceya (nilotinib)

+

tadalafil

1 interaction

Monitor/Modify Tx

nilotinib + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metab. inhibited)

• tafasitamab
Nilceya (nilotinib)

+

tafasitamab

1 interaction

Monitor/Modify Tx

nilotinib + tafasitamab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• tamsulosin
Nilceya (nilotinib)

+

tamsulosin

1 interaction

Monitor/Modify Tx

nilotinib + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (incl. orthostasis, syncope), other adverse effects (hepatic metab. inhibited)

• telmisartan
Nilceya (nilotinib)

+

telmisartan

1 interaction

Monitor/Modify Tx

nilotinib + telmisartan

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• temsirolimus
Nilceya (nilotinib)

+

temsirolimus

1 interaction

Monitor/Modify Tx

nilotinib + temsirolimus

monitor CBC, bleeding s/sx; consider decr. temsirolimus dose: combo may incr. temsirolimus and active metabolite sirolimus levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• tenecteplase
Nilceya (nilotinib)

+

tenecteplase

1 interaction

Monitor/Modify Tx

nilotinib + tenecteplase

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• teplizumab
Nilceya (nilotinib)

+

teplizumab

1 interaction

Monitor/Modify Tx

nilotinib + teplizumab

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• terbutaline
Nilceya (nilotinib)

+

terbutaline

1 interaction

Monitor/Modify Tx

nilotinib + terbutaline

monitor ECG, electrolytes: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

• teriflunomide
Nilceya (nilotinib)

+

teriflunomide

1 interaction

Monitor/Modify Tx

nilotinib + teriflunomide

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• tezacaftor/ivacaftor
Nilceya (nilotinib)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + tezacaftor/ ivacaftor

decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• thalidomide
Nilceya (nilotinib)

+

thalidomide

1 interaction

Monitor/Modify Tx

nilotinib + thalidomide

monitor CBC, calcium: combo may incr. risk of myelosuppression, hypocalcemia (additive effects)

• ticagrelor
Nilceya (nilotinib)

+

ticagrelor

1 interaction

Monitor/Modify Tx

nilotinib + ticagrelor

monitor bleeding s/sx: combo may incr. ticagrelor levels, risk of dyspnea, GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• tick-borne encephalitis vaccine
Nilceya (nilotinib)

+

tick-borne encephalitis vaccine

1 interaction

Monitor/Modify Tx

nilotinib + tick-borne encephalitis vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• tirofiban
Nilceya (nilotinib)

+

tirofiban

1 interaction

Monitor/Modify Tx

nilotinib + tirofiban

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tisotumab vedotin
Nilceya (nilotinib)

+

tisotumab vedotin

1 interaction

Monitor/Modify Tx

nilotinib + tisotumab vedotin

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• tivozanib
Nilceya (nilotinib)

+

tivozanib

1 interaction

Monitor/Modify Tx

nilotinib + tivozanib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• tobramycin
Nilceya (nilotinib)

+

tobramycin

1 interaction

Monitor/Modify Tx

nilotinib + tobramycin

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• tocilizumab
Nilceya (nilotinib)

+

tocilizumab

1 interaction

Monitor/Modify Tx

nilotinib + tocilizumab

monitor CBC, bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of myelosuppression, GI ulceration, perforation, bleeding, incl. life-threatening (hepatic metab. altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• tofacitinib
Nilceya (nilotinib)

+

tofacitinib

1 interaction

Monitor/Modify Tx

nilotinib + tofacitinib

monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib dose as follows: RHEUMATOID or PSORIATIC ARTHRITIS: decr. tofacitinib dose to 5 mg qd; ULCERATIVE COLITIS: decr. tofacitinib 22 mg qd dose to 11 mg qd; decr. tofacitinib 11 mg qd dose to 5 mg qd; decr. tofacitinib 10 mg bid dose to 5 mg bid; decr. tofacitinib 5 mg bid dose to 5 mg qd; JUVENILE IDIOPATHIC ARTHRITIS: decr. usual tofacitinib bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metab. inhibited, additive effects)

• tolmetin
Nilceya (nilotinib)

+

tolmetin

1 interaction

Monitor/Modify Tx

nilotinib + tolmetin

monitor potassium, bleeding s/sx: combo may incr. risk of hyperkalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• tolterodine
Nilceya (nilotinib)

+

tolterodine

1 interaction

Monitor/Modify Tx

nilotinib + tolterodine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• topiramate
Nilceya (nilotinib)

+

topiramate

1 interaction

Monitor/Modify Tx

nilotinib + topiramate

monitor potassium: combo may decr. nilotinib levels, efficacy; may incr. risk of hypokalemia (hepatic metab. induced; additive effects)

• torsemide
Nilceya (nilotinib)

+

torsemide

1 interaction

Monitor/Modify Tx

nilotinib + torsemide

monitor potassium, calcium, sodium: combo may incr. risk of hypokalemia, hypocalcemia, hyponatremia (additive effects)

• tovorafenib
Nilceya (nilotinib)

+

tovorafenib

1 interaction

Monitor/Modify Tx

nilotinib + tovorafenib

monitor bleeding s/sx: combo may decr. nilotinib levels, efficacy; incr. risk of GI or other bleeding, incl. life-threatening (hepatic metab. induced; additive effects)

• trabectedin
Nilceya (nilotinib)

+

trabectedin

1 interaction

Monitor/Modify Tx

nilotinib + trabectedin

monitor CBC, cardiac fxn, LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metab. inhibited)

• trametinib
Nilceya (nilotinib)

+

trametinib

1 interaction

Monitor/Modify Tx

nilotinib + trametinib

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• trandolapril
Nilceya (nilotinib)

+

trandolapril

1 interaction

Monitor/Modify Tx

nilotinib + trandolapril

monitor potassium: combo may incr. risk of hyperkalemia (additive effects)

• trastuzumab
Nilceya (nilotinib)

+

trastuzumab

1 interaction

Monitor/Modify Tx

nilotinib + trastuzumab

monitor potassium: combo may incr. risk of hypokalemia (additive effects)

• treprostinil
Nilceya (nilotinib)

+

treprostinil

1 interaction

Monitor/Modify Tx

nilotinib + treprostinil

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• triamcinolone
Nilceya (nilotinib)

+

triamcinolone

1 interaction

Monitor/Modify Tx

nilotinib + triamcinolone

monitor potassium, bleeding s/sx: combo may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• triamterene
Nilceya (nilotinib)

+

triamterene

1 interaction

Monitor/Modify Tx

nilotinib + triamterene

monitor potassium, sodium: combo may incr. risk of severe hyperkalemia, hyponatremia (additive effects)

• triazolam
Nilceya (nilotinib)

+

triazolam

1 interaction

Monitor/Modify Tx

nilotinib + triazolam

monitor resp. rate; consider decr. triazolam dose: combo may incr. triazolam levels, risk of CNS and resp. depression, psychomotor impairment, other adverse effects (hepatic metab. inhibited)

• trimethoprim
Nilceya (nilotinib)

+

trimethoprim

1 interaction

Monitor/Modify Tx

nilotinib + trimethoprim

monitor CBC, potassium: combo may incr. risk of myelosuppression, hyperkalemia (additive effects)

• typhoid vaccine
Nilceya (nilotinib)

+

typhoid vaccine

1 interaction

Monitor/Modify Tx

nilotinib + typhoid vaccine

if possible, vaccinate at least 2wk before starting nilotinib tx; otherwise, consider post-immunization titer check or revaccination after immunocompetence restored: combo may result in inadequate vaccine response (immunosuppressive effects)

• ubrogepant
Nilceya (nilotinib)

+

ubrogepant

1 interaction

Monitor/Modify Tx

nilotinib + ubrogepant

limit ubrogepant dose to 50 mg, may give second 50 mg dose after 24h if needed: combo may incr. ubrogepant levels, risk of adverse effects (hepatic metab. inhibited)

• upadacitinib
Nilceya (nilotinib)

+

upadacitinib

1 interaction

Monitor/Modify Tx

nilotinib + upadacitinib

monitor CBC, bleeding s/sx: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, GI ulceration, perforation, bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, additive effects)

• vadadustat
Nilceya (nilotinib)

+

vadadustat

1 interaction

Monitor/Modify Tx

nilotinib + vadadustat

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• valbenazine
Nilceya (nilotinib)

+

valbenazine

1 interaction

Monitor/Modify Tx

nilotinib + valbenazine

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• valproic acid
Nilceya (nilotinib)

+

valproic acid

1 interaction

Monitor/Modify Tx

nilotinib + valproic acid

monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, GI or other bleeding, incl. life-threatening (additive effects)

• vamorolone
Nilceya (nilotinib)

+

vamorolone

1 interaction

Monitor/Modify Tx

nilotinib + vamorolone

monitor potassium, bleeding s/sx: combo may decr. nilotinib levels, efficacy; may incr. risk of hypokalemia, GI ulceration, perforation, bleeding, incl. life-threatening (hepatic metab. possibly induced; additive effects)

• vancomycin
Nilceya (nilotinib)

+

vancomycin

1 interaction

Monitor/Modify Tx

nilotinib + vancomycin

VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

• vanzacaftor/tezacaftor/deutivacaftor
Nilceya (nilotinib)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

nilotinib + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metab. inhibited)

• vasopressin
Nilceya (nilotinib)

+

vasopressin

1 interaction

Monitor/Modify Tx

nilotinib + vasopressin

monitor sodium: combo may incr. risk of hyponatremia (additive effects)

• venlafaxine
Nilceya (nilotinib)

+

venlafaxine

1 interaction

Monitor/Modify Tx

nilotinib + venlafaxine

monitor ECG, electrolytes, bleeding s/sx: combo may incr. risk of QT prolongation, cardiac arrhythmias, hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• verapamil
Nilceya (nilotinib)

+

verapamil

1 interaction

Monitor/Modify Tx

nilotinib + verapamil

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, AV block, myelosuppression, other adverse effects (hepatic metab. inhibited)

• vilanterol inhaled
Nilceya (nilotinib)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

nilotinib + vilanterol inhaled

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

• vilazodone
Nilceya (nilotinib)

+

vilazodone

1 interaction

Monitor/Modify Tx

nilotinib + vilazodone

monitor bleeding s/sx, sodium: combo may incr. vilazodone levels, risk of GI or other bleeding (incl. life-threatening), hyponatremia, other adverse effects (hepatic metab. inhibited, additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• vinblastine
Nilceya (nilotinib)

+

vinblastine

1 interaction

Monitor/Modify Tx

nilotinib + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• vincristine
Nilceya (nilotinib)

+

vincristine

1 interaction

Monitor/Modify Tx

nilotinib + vincristine

monitor CBC: combo may incr. vincristine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinorelbine
Nilceya (nilotinib)

+

vinorelbine

1 interaction

Monitor/Modify Tx

nilotinib + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metab. inhibited)

• vinpocetine
Nilceya (nilotinib)

+

vinpocetine

1 interaction

Monitor/Modify Tx

nilotinib + vinpocetine

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• voclosporin
Nilceya (nilotinib)

+

voclosporin

1 interaction

Monitor/Modify Tx

nilotinib + voclosporin

monitor ECG, electrolytes, renal fxn; decr. voclosporin morning dose to 15.8 mg and evening dose to 7.9 mg: combo may incr. voclosporin levels, risk of QT prolongation, cardiac arrhythmias, severe hyperkalemia, serious infection, nephrotoxicity, other adverse effects (hepatic metab. inhibited, additive effects)

• vorapaxar
Nilceya (nilotinib)

+

vorapaxar

1 interaction

Monitor/Modify Tx

nilotinib + vorapaxar

monitor bleeding s/sx: combo may incr. risk of GI or other bleeding, incl. life-threatening (additive effects)

• vortioxetine
Nilceya (nilotinib)

+

vortioxetine

1 interaction

Monitor/Modify Tx

nilotinib + vortioxetine

monitor sodium, bleeding s/sx: combo may incr. risk of hyponatremia, GI or other bleeding, incl. life-threatening (additive effects, antiplatelet effects augmented by inhibition of platelet serotonin uptake)

• warfarin
Nilceya (nilotinib)

+

warfarin

1 interaction

Monitor/Modify Tx

nilotinib + warfarin

monitor INR, bleeding s/sx, especially during initiation/titration: combo may incr. warfarin levels, risk of GI or other bleeding (incl. life-threatening), other adverse effects (hepatic metab. inhibited, synergistic effects)

• willow bark
Nilceya (nilotinib)

+

willow bark

1 interaction

Monitor/Modify Tx

nilotinib + willow bark

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects, willow bark may contain salicylates)

• zanubrutinib
Nilceya (nilotinib)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

nilotinib + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC, bleeding s/sx: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, GI or other bleeding (incl. life-threatening), other adverse effects; may decr. nilotinib levels, efficacy (hepatic metab. inhibited, additive effects; hepatic metab. induced)

• zidovudine
Nilceya (nilotinib)

+

zidovudine

1 interaction

Monitor/Modify Tx

nilotinib + zidovudine

monitor CBC: combo may incr. risk of myelosuppression (additive effects)

• ziv-aflibercept
Nilceya (nilotinib)

+

ziv-aflibercept

1 interaction

Monitor/Modify Tx

nilotinib + ziv-aflibercept

monitor bleeding s/sx: combo may incr. risk of GI ulceration, perforation, bleeding, incl. life-threatening (additive effects)

• zoledronic acid
Nilceya (nilotinib)

+

zoledronic acid

1 interaction

Monitor/Modify Tx

nilotinib + zoledronic acid

monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

• zonisamide
Nilceya (nilotinib)

+

zonisamide

1 interaction

Monitor/Modify Tx

nilotinib + zonisamide

monitor potassium: combo may incr. risk of hypokalemia (additive effects)